Article Information
History
- September 27, 2021.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Matthew Poremba1,
- Matthew Dehner1,
- Alexandra Perreiter1,
- Ashley Semma1,
- Kimberly Mills1 and
- George Sakoulas1,2,*
- 1Sharp Memorial Hospital, 7901 Frost Street, San Diego, CA 92123
- 2Collaborative to Halt Antibiotic-Resistant Microbes (CHARM), Department of Pediatrics, University of California San Diego School of Medicine, La Jolla, CA
- ↵*Correspondence:
George Sakoulas, MD, UCSD School of Medicine Biomedical Research Facility II, Room 4114, 9500 Gilman Drive, Mail Code 0760, La Jolla, CA 92093-0760, Phone: (858) 534-2325; FAX: (858) 246-1868; Email: gsakoulas{at}health.ucsd.edu
Posted September 27, 2021.
Intravenous Immunoglobulin (IVIG) in Treating Non-ventilated COVID-19 Patients with Moderate to Severe Hypoxia is Pharmacoeconomically Favorable When Appropriately Targeted
